Frazier Life Sciences Management, L.P. Trevi Therapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.7 Billion
- Q2 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 7,381,090 shares of TRVI stock, worth $24.7 Million. This represents 1.3% of its overall portfolio holdings.
Number of Shares
7,381,090
Previous 7,381,090
-0.0%
Holding current value
$24.7 Million
Previous $25.5 Million
13.62%
% of portfolio
1.3%
Previous 1.34%
Shares
5 transactions
Others Institutions Holding TRVI
# of Institutions
74Shares Held
54.3MCall Options Held
15.6KPut Options Held
0-
Nea Management Company, LLC Timonium, MD11.4MShares$38 Million3.2% of portfolio
-
Rubric Capital Management LP New York, NY5.03MShares$16.8 Million0.44% of portfolio
-
Viking Global Investors LP4.4MShares$14.7 Million0.05% of portfolio
-
Vr Adviser, LLC New York, NY3.42MShares$11.4 Million1.12% of portfolio
-
Black Rock Inc. New York, NY3.14MShares$10.5 Million0.0% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $195M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...